CytoMed Therapeutics Has Acquired The License And Certain Assets Of Cellsafe International, A Malaysian Cord Blood Bank, Deal Terms Were Not Disclosed
CytoMed Therapeutics Has Acquired The License And Certain Assets Of Cellsafe International, A Malaysian Cord Blood Bank, Deal Terms Were Not Disclosed
CytoMed Therapeutics已收购了马来西亚脐带血银行Cellsafe International的许可证和部分资产，交易条款未透露。
- The acquisition includes (i) a cord blood banking licence issued by Malaysia's Ministry of Health, (ii) cryopreservation equipment with more than 12,000 cord blood units, and (iii) two freehold real estate properties totalling 189 square metres in which the operation is situated.
- This acquisition will expand CytoMed's strategy in cell therapies as it now has access to rare and precious naïve cord blood donated for research and development. There are abundant clinical publications and evidence that cord blood offers a wide range of opportunities in the fields of regenerative medicine and aging diseases, including auto-immune diseases. This new biotechnology arm will be undertaken through CytoMed's subsidiary, LongevityBank Pte Ltd. The latter is the holding company of IPSC Depository Sdn Bhd which holds the cord blood banking licence issued by the Ministry of Health, Malaysia.
- 该收购包括（i）由马来西亚卫生部颁发的脐带血银行许可证，（ii）超过12,000个脐带血单位的冷冻设备，以及（iii）两处总面积为189平方米的永久产权房地产物业，其中设有运营中心。
- 这项收购将扩大CytoMed在电芯疗法领域的策略，因为现在它可以接触用于研究和开发的稀有且珍贵的原生脐带血样本。有大量的临床出版物和证据表明，脐带血在再生医学和衰老疾病领域（包括自身免疫疾病）提供了广泛的机会。这项新的生物技术业务将通过CytoMed的子公司LongevityBank Pte Ltd进行。后者是IPSC Depository Sdn Bhd的控股公司，后者持有马来西亚卫生部颁发的脐带血银行许可证。
资讯热榜
更新时间